Autoimmune hemolytic anemia screening
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shyam Patel [2], Irfan Dotani [3]
Overview
Screening for autoimmune hemolytic anemia is not currently done routinely.
Screening
- Screening for autoimmune hemolytic anemia is not currently done routinely.
- The incidence of autoimmune hemolytic anemia is low enough such that screening measures are not indicated.
- However, screening is done for other conditions associated with hemolytic anemia, such as sickle cell disease.[1]
- One important manifestation of sickle cell disease is hyperhemolytic crisis, in which there is massive hemolysis.
- The United States and the United Kingdom have formal screening processes in place for sickle cell disease for newborns.
- Screening for sickle cell disease can prevent early childhood morbidity and mortality.
- Less developed countries, such as countries in Africa, do not have formal screening measures for sickle cell disease in place.[1]
References
- ↑ 1.0 1.1 Alapan Y, Fraiwan A, Kucukal E, Hasan MN, Ung R, Kim M; et al. (2016). “Emerging point-of-care technologies for sickle cell disease screening and monitoring”. Expert Rev Med Devices. 13 (12): 1073–1093. doi:10.1080/17434440.2016.1254038. PMC 5166583. PMID 27785945.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH